Who
Ingrid Delaet
Chief Regulatory Officer
Company insider
Files Form 4 as: Chief Regulatory Officer, Neurocrine Biosciences.
In numbers
- Trades disclosed
- 148
- Buys
- 0
- Sells
- 29
- Bought
- $0
- Sold
- $12.7M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 13 Feb 2023
- Last trade
- 11 Sep 2026
- Last filed
- 15 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —4,483 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $378K2,419 at $156.22 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code A | —4,483 at $0.00 | filing |
| 11 Sep 2026filed 15 Sep 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code F | $378K2,419 at $156.22 | filing |
| 10 Jul 2026filed 13 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $463K4,367 at $106.02 | filing |
| 10 Jul 2026filed 13 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $791K4,367 at $181.02 | filing |
| 10 Jul 2026filed 13 Jul 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,367 at $0.00 | filing |
| 10 Jul 2026filed 13 Jul 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —4,367 at $0.00 | filing |
| 10 Jul 2026filed 13 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $463K4,367 at $106.02 | filing |
| 10 Jul 2026filed 13 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $791K4,367 at $181.02 | filing |
| 9 Jul 2026filed 9 Jul 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,433 at $0.00 | filing |
| 9 Jul 2026filed 9 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $873K8,433 at $103.52 | filing |
| 9 Jul 2026filed 9 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $1.5M8,433 at $178.72 | filing |
| 9 Jul 2026filed 9 Jul 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —8,433 at $0.00 | filing |
| 9 Jul 2026filed 9 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $873K8,433 at $103.52 | filing |
| 9 Jul 2026filed 9 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $1.5M8,433 at $178.72 | filing |
| 8 Jul 2026filed 9 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Code M | $283K2,737 at $103.52 | filing |
| 8 Jul 2026filed 9 Jul 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,737 at $0.00 | filing |
| 8 Jul 2026filed 9 Jul 2026 | NBIX Neurocrine BiosciencesPharmaceuticals | SEC FORM 4 Sold | $489K2,737 at $178.54 | filing |
| 8 Jul 2026filed 9 Jul 2026 | NBIX Neurocrine Biosciencesoption or derivative · Pharmaceuticals | SEC FORM 4 Code M | —2,737 at $0.00 | filing |
News
No headline names them, or the companies they trade most, lately.